Anderson WF. September 14, 1990: the beginning. Hum Gene Ther. 1990 Winter;1(4):371–2.

Lapteva L, Purohit-Sheth T, Serabian M, et al. Clinical development of gene therapies: the first three decades and counting. Mol Ther Methods Clin Dev. 2020;19:387–97.

CAS  PubMed  PubMed Central  Google Scholar 

Dunbar CE, High KA, Joung JK, et al. Gene therapy comes of age. Science. 2018;359(6372):eaan4672.

PubMed  Google Scholar 

Bulaklak K, Gersbach CA. The once and future gene therapy. Nat Commun. 2020;11:5820.

CAS  PubMed  PubMed Central  Google Scholar 

Food US. January and Drug Administration. Long Term Follow-Up After Administration of Human Gene Therapy Products (Guidance for Industry). 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/long-term-follow-after-administration-human-gene-therapy-products

Marta C, Bruno S, Ana PM. Regulatory and scientific advancements in gene therapy; State-of-the-Art of clinical applications and of the supporting European regulatory framework. Front Med. 2017;4:182.

Google Scholar 

Salima HBA, Alexandrine G, Gary PW et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.Clinical trial. 2008; 118(9): 3132–42.

Marshall E. Gene therapy death prompts review of adenovirus vector. Science. 1999;286(5448):2244–5.

CAS  PubMed  Google Scholar 

Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so Far. Nat Rev Clin Oncol. 2023;20(6):359–71.

CAS  PubMed  PubMed Central  Google Scholar 

Laetsch TW, Maude SL, Rives S, et al. Three-Year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023;41(9):1664–9.

CAS  PubMed  Google Scholar 

Cordeiro A, Bezerra ED, Hirayama AV, et al. Late events after treatment with CD19-Targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transpl. 2020;26(1):26–33.

CAS  Google Scholar 

Mendell JR, Al-Zaidy SA, Lehman KJ, et al. Five-Year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021;78(7):834–41.

PubMed  Google Scholar 

Gaudet D, Stroes ES, Méthot J, et al. Long-Term retrospective analysis of gene therapy with alipogene Tiparvovec and its effect on lipoprotein lipase Deficiency-Induced pancreatitis. Hum Gene Ther. 2016;27(11):916–25.

CAS  PubMed  Google Scholar 

Migliavacca M, Barzaghi F, Fossati C, et al. Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency. Nat Med. 2024;30:488–97.

CAS  PubMed  PubMed Central  Google Scholar 

Day JW, Mendell JR, Mercuri E, et al. Clinical trial and postmarketing safety of onasemnogene abeparvovec therapy. Drug Saf. 2021;44:1109–19.

CAS  PubMed  PubMed Central  Google Scholar 

Migliavacca M, Barzaghi F, Fossati C, et al. Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency. Nat Med. 2024;30(2):488–97.

CAS  PubMed  PubMed Central  Google Scholar 

Sardella M, Belcher G. Pharmacovigilance of medicines for rare and ultrarare diseases. Therapeutic Adv Drug Saf. 2018;9(11):631–8.

Google Scholar 

European Medicines Agency. Guideline on safety and efficacy follow-up and risk management of Advanced Therapy Medicinal Products. 25. Jan 2018. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-safety-and-efficacy-follow-and-risk-management-advanced-therapy-medicinal-products-revision-1_en.pdf

The International Council for Harmonisation (ICH). Guideline E2D. Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting. 12 Nov 2003 https://database.ich.org/sites/default/files/E2D_Guideline.pdf

Postmarketing Safety Reporting for Human Drug and Biological Products Including VaccinesDraft Guidance for Industry. US FDA. Mar 2001 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarketing-safety-reporting-human-drug-and-biological-products-including-vaccines

European Medicines Agency. Guidance for Industry Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines. DRAFT GUIDANCE. https://www.ema.europa.eu/en/human-regulatory-overview/research-development/pharmacovigilance-research-development/eudravigilance/eudravigilance-electronic-reporting

World Health Organization-Uppsala Monitoring Centre. Guideline for using VigiBase data in studies. https://who-umc.org/media/05kldqpj/guidelineusingvigibaseinstudies.pdf

Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Ther Innov Regul Sci. 2008;42:409–19.

Google Scholar 

U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products

European Medicines Agency. CAT quarterly highlights and approved ATMPs. 11. Oct 2023. https://www.ema.europa.eu/en/documents/committee-report/cat-quarterly-highlights-and-approved-atmps-october-2023_en.pdf

Palomo GM, Pose-Boirazian T, Naumann-Winter F, et al. The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA committee for orphan medicinal products. Mol Ther. 2023;31(12):3414–23.

CAS  PubMed  PubMed Central  Google Scholar 

De Luca M, Cossu G. Cost and availability of novel cell and gene therapies: can we avoid a catastrophic second Valley of death? can we avoid a catastrophic second Valley of death? EMBO Rep. 2023;24(2):e56661.

PubMed  PubMed Central  Google Scholar 

Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther. 1998;20(Suppl C):C40–4.

CAS  PubMed  Google Scholar 

Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the united states, 1969–2002: the importance of reporting suspected reactions. Arch Intern Med. 2005;165(12):1363–9.

PubMed  Google Scholar 

Wakao R, Taavola H, Sandberg L, et al. Data-Driven identification of adverse event reporting patterns for Japan in vigibase, the WHO global database of individual case safety reports. Drug Saf. 2019;42(12):1487–98.

CAS  PubMed  PubMed Central  Google Scholar 

Fusaroli M, Isgrò V, Cutroneo PM, et al. Post-Marketing surveillance of CAR-T-Cell therapies: analysis of the FDA adverse event reporting system (FAERS) database. Drug Saf. 2022;45(8):891–908.

CAS  PubMed  PubMed Central  Google Scholar 

Bergvall T, Norén GN, Lindquist M, vigiGrade:. A tool to identify Well-Documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37(1):65–77.

PubMed  Google Scholar 

Chaipichit N, Krska J, Pratipanawatr T, et al. A qualitative study to explore how patients identify and assess symptoms as adverse drug reactions. Eur J Clin Pharmacol. 2014;70(5):607–15.

CAS  PubMed  Google Scholar 

World Health Organization-Uppsala Monitoring Centre. VigiBase Frequently Asked Questions. https://who-umc.org/vigibase/vigibase-faqs/